Esomeprazole and Gastric Emptying of Beer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00472550|
Recruitment Status : Completed
First Posted : May 11, 2007
Last Update Posted : May 11, 2007
To investigate the effect of 20 mg esomeprazole daily for one week on gastric emptying of 500 ml beer, the consecutive blood alcohol levels, the gastroesophageal reflux and plasma levels of gastrin and CCK in a randomized, placebo-controlled, double-blinded manner in 16 healthy male volunteers.
The combined taking of esomeprazole and beer will inhibit gastric emptying as compared to the intake of beer alone. This will induce a delay of the ethanol absorption and of the consecutive blood ethanol concentrations. Gastric acid secretion after beer will be reduced after esomeprazole treatment. Therefore, gastroesophageal acid reflux will be reduced after the combined taking. We speculate that gastrin, but not CCK plasma levels, will be increased after the combined taking as compared to beer alone. Both, beer and PPIs, have stimulatory effects on gastrin release. However, the secretion of CCK from duodenal CCK-cells is inhibited when gastric emptying is prolonged.
|Condition or disease||Intervention/treatment||Phase|
|Gastroesophageal Reflux Heartburn||Drug: esomeprazole 20 mg||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers|
|Study Start Date :||January 2006|
|Actual Study Completion Date :||November 2006|
- Gastric emptying time, gastroesophageal reflux [ Time Frame: 3h ]
- blood ethanol concentration, CCK-levels, gastrin-levels, dyspeptic symptoms [ Time Frame: 3h ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00472550
|Dep. Medicine II, University Hospital Mannheim|
|Mannheim, Germany, 68167|
|Principal Investigator:||Andreas Franke, MD||Dep. Medicine II, University hospital Mannheim|